Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10201/72040
Twittear
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Andergassen, Ulrich | - |
dc.contributor.author | Kölbl, A. C. | - |
dc.contributor.author | Zebisch, M. | - |
dc.contributor.author | Heublein, Sabine | - |
dc.contributor.author | Hutter, S. | - |
dc.contributor.author | Ilmer, M. | - |
dc.contributor.author | Schindlbeck, C. | - |
dc.contributor.author | Friese, K. | - |
dc.contributor.author | Jeschke, U. | - |
dc.date.accessioned | 2019-06-13T17:02:57Z | - |
dc.date.available | 2019-06-13T17:02:57Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Histology & Histopathology, Vol. 19, nº 7 (2014) | es |
dc.identifier.issn | 1699-5848 | - |
dc.identifier.issn | 0213-3911 | - |
dc.identifier.uri | http://hdl.handle.net/10201/72040 | - |
dc.description.abstract | Disseminated tumour cells (DTCs) in the bone marrow derive from many primary tumours, such as breast cancer. Their mere existence hints to present or future metastasis and implicates a worse prognosis for the patient. DTCs may possess different characteristics in comparison to the primary tumour due to events like Epithelial-Mesenchymal-Transition. Therefore these cells might be able to survive chemotherapy and cause relapses of the disease at a later point. We aimed to detect and further characterise DTCs by an immunostaining approach with three different antigen markers (Her-2, MUC-1 and TF, also known as CD176). For that reason, bone marrow of 41 breast cancer patients was obtained during surgery; DTCs were enriched by density gradient centrifugation and cytospins were prepared. After fixation, immunofluorescent double-stainings were carried out with antibodies against CD176 in combination with HER-2 or MUC-1. Cells co-expressing two antigens were found in all staining combinations (Her-2 and CD176: 46.14%; MUC-1 and CD176: 18.15% of all cases). Cells that stained for a single antigen only were also found (Her-2: 36.86%; MUC-1: 34.45%; CD176: 29.65% of all cases). Significant correlations between the stainings of all markers could be shown (p<0,001). In conclusion, Thomsen-Friedenreich Antigen (TF, CD176) is a promising marker in combination with the established marker Her-2 and other markers like MUC-1. These results may serve as a basis for future DTC detection routines and help to individualize medical treatment, reducing side effects and increasing the efficiency of the therapy. | es |
dc.format | application/pdf | es |
dc.format.extent | 11 | es |
dc.language | eng | es |
dc.publisher | F. Hernández y Juan F. Madrid. Universidad de Murcia. Departamento de Biología Celular e Histología | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Imunostaining | es |
dc.subject | Bone marrow | es |
dc.subject | DTCs | es |
dc.subject | Thomsen-Friedenreich-antigen | es |
dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina | es |
dc.title | Detection and characterisation of disseminated tumour cells in bone marrow of breast cancer patients by immunostaining of Her-2 and MUC-1 in combination with Thomsen-Friedenreich (CD176) | es |
dc.type | info:eu-repo/semantics/article | es |
Aparece en las colecciones: | Vol.29, nº 7 (2014) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Andergassen-29-913-923-2014.pdf | 6,89 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons